HT
BPMC

Headlands Technologies’s Blueprint Medicines BPMC Stock Holding History

Headlands Technologies’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-185
Closed -$23.7K – 694
2025
Q2 		$23.7K Sell
185
-751
-80% -$78K ﹤0.01% 905
2025
Q1 		$82.8K Buy
936
+187
+25% +$18.2K 0.01% 627
2024
Q4 		$65.3K Buy
+749
New +$68.6K 0.01% 762
2024
Q2 		– Sell
-667
Closed -$63.3K – 1177
2024
Q1 		$63.3K Buy
667
+342
+105% +$29.3K 0.02% 658
2023
Q4 		$30K Sell
325
-1,586
-83% -$103K 0.01% 607
2023
Q3 		$96K Buy
1,911
+489
+34% +$26.1K 0.05% 312
2023
Q2 		$89.9K Buy
+1,422
New +$77.3K 0.03% 398

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Headlands Technologies's BPMC Position: Q3 2025 in Review

Headlands Technologies sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 185 shares — an estimated $23.7K sold.

Headlands Technologies first reported a position in BPMC in Q2 2023 and held it in 7 quarters. The position peaked at $96K in Q3 2023. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Headlands Technologies reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Headlands Technologies sold 185 Blueprint Medicines shares in Q3 2025, an estimated $23.7K.
  • Headlands Technologies first reported a position in Blueprint Medicines in Q2 2023 and held it in 7 quarters.
  • Headlands Technologies's Blueprint Medicines position peaked at $96K in Q3 2023.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Headlands Technologies's 13F filing for Q3 2025, filed 12 Nov 2025.